Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13801507 | 0.89 | POLB (0.33) | KDM4EPOLBALDH1A1HSD17B10MAPT | |
| SCHEMBL13801505 | 0.87 | ALDH1A1 (0.36) | KDM4EPOLBALDH1A1HSD17B10HPGD | |
| SCHEMBL8279984 | 0.82 | GPR35 (0.40) | KDM4EPOLBALDH1A1HSD17B10HPGD | |
| SCHEMBL9008078 | 0.73 | POLB (0.47) | KDM4EPOLBALDH1A1MAPTLMNA | |
| SCHEMBL9008105 | 0.72 | NPSR1 (0.41) | KDM4EPOLBALDH1A1HSD17B10HPGD | |
| SCHEMBL9008171 | 0.70 | POLB (0.37) | KDM4EPOLBALDH1A1MAPTL3MBTL1 | |
| SCHEMBL9008121 | 0.70 | ALDH1A1 (0.38) | KDM4EPOLBALDH1A1HPGDMAPT | |
| SCHEMBL9008083 | 0.70 | POLB (0.37) | KDM4EPOLBALDH1A1MAPTLMNA | |
| SCHEMBL8279983 | 0.68 | POLB (0.35) | KDM4EPOLBALDH1A1L3MBTL1 | |
| SCHEMBL12690123 | 0.66 | GPR84 (0.35) | POLBALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163505-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163505-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | KDM4E 4839/4885PIK3CA 3809/4885POLB 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.